SABCS 2019
Read the full Report (pdf)
San Antonio Breast Cancer Symposium
10–14 December 2019 San Antonio, Texas, USA
Featured articles
CONTENTS
Online First
Screening, Detection, and Diagnosis
MRI and 14G biopsies are not accurate enough in pCR detection
Breast cancer incidence decreased by oestrogen alone but increased by adding progestin
Tamoxifen monotherapy may mean undertreatment for some luminal breast cancer patients
Phase 2 Trial Update
High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients
HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients
Residual cancer burden is a predictor for all-type breast cancer patients
Phase 3 Trial Update
S-1 shows promising results in combination with endocrine therapy
Better outcomes with oral paclitaxel than intravenous paclitaxel in metastatic breast cancer
Subcutaneous pertuzumab + trastuzumab non-inferior to the IV combination
Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer
Long-Term Study Results
Anastrozole yields long term effects in the prevention of breast cancer occurrence
Partial breast irradiation could be as effective as whole breast irradiation
Sensory peripheral neuropathy after taxane treatment is not uncommon
No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide
Triple-Negative Breast Cancer
No higher pathologic complete response with atezolizumab added to chemotherapy
Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer
HER2-Positive Breast Cancer
Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer
